CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS

NACompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 4, 2017

Study Completion Date

June 21, 2017

Conditions
Hepatitis C Virus Infection, Response to Therapy ofHuman Immunodeficiency Virus
Interventions
OTHER

Usual care plus peer-mentors

Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.

OTHER

Usual care plus incentives

Participants are given incentives after completing treatment goals.

OTHER

Usual Care

Participants receive standard of care in the clinic from their health care team.

Trial Locations (1)

21287

Johns Hopkins Hospital : The John G. Bartlett Specialty Practice, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Johns Hopkins University

OTHER

NCT02402218 - CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS | Biotech Hunter | Biotech Hunter